hotspot -WSS

hotspot

author：comprehensive 2025-09-27 22:46:03 - browse：6

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Creating egg and sperm cells from stem cells raises ethical issues

entertainment

focus

WSS

As Taiwan prepares for anti

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Methadone treatment changes are coming. Do they go far enough?

White House launches permanent pandemic office

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Health AI adoption puts security, privacy startups on investors' radar

leisure time

hotspot

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Court strikes down limits on filming of police in Arizona

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Leading voice in opioid treatment defends methadone clinic system

Bright Health sells Medicare Advantage business to Molina

U.K. researchers warn about biases in medical devices, algorithms

23andMe had bad news about my health. I wish a person had delivered it

AstraZeneca to buy developer of next

At least 13 dead in Texas as scorching temps continue

Gene editing the human germline: What are the risks?

focus

Review: 'Barbie' will hit you like a shot in the heart

Gene editing the human germline: What are the risks?

Methadone treatment changes are coming. Do they go far enough?

AstraZeneca to buy developer of next

Creating egg and sperm cells from stem cells raises ethical issues

7 of the most gruesome medical devices in history

entertainment

hotspot

focus

hotspot